FBGL vs NIVF: Micro-Caps Facing Compliance Challenges After Reverse Splits
Key Takeaways
- FBGL (FBS Global) is a Singapore-based green building and interior fit-out contractor, while NIVF (NewGenIvf Group) is an assisted-reproduction and fertility-services provider across Southeast Asia.
- Both are Nasdaq Capital Market micro-caps that recently relied on reverse stock splits to address exchange listing requirements.
- FBGL regained Nasdaq minimum bid price compliance, whereas NIVF has traded near historic lows amid repeated dilution and multiple reverse splits.
- FBGL has declined roughly 47% over the past year, while NIVF has fallen more than 99% over the same period.
- Neither name currently demonstrates positive operating momentum, making this a comparison of turnaround potential against elevated risk.
Introduction
Investors scanning the Nasdaq Capital Market for contrarian or turnaround ideas frequently run into small, deeply discounted names where the risks often outweigh the potential rewards. This comparison looks at two such companies: FBGL, a Singapore-based construction and building-services operator, and NIVF, a fertility-services group that has branched into other areas. Although they operate in completely different sectors, both have dealt with reverse stock splits, compliance issues, and steep price drops in recent weeks.
FBGL Overview and Recent Performance
FBS Global Limited, trading as FBGL, is a Singapore-based building contractor and interior fit-out specialist that works on institutional, residential, commercial, and industrial projects. The company also supplies building materials and precast concrete components and offers construction, waste-recycling, and pavement consultancy services. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent trading has been influenced by listing-compliance steps. FBS Global carried out a 1-for-10 share consolidation in late September 2026 and later confirmed it had met Nasdaq’s minimum bid price requirement, closing the prior deficiency. Even so, FBGL has declined roughly 47% over the trailing 52 weeks and trades below its 50-day and 200-day moving averages. The company shows negative return on equity and negative operating cash flow, which have pressured sentiment despite a relatively modest debt load compared with book value.
NIVF Overview and Recent Performance
NewGenIvf Group Limited, trading as NIVF, offers assisted-reproduction services including in vitro fertilization through clinics in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company has also outlined plans in real estate development and digital-asset ventures, including a stake in an artificial-intelligence-related entity. From what I see, the business model has broadened beyond its core healthcare focus.
Market activity has featured notable volatility and ongoing share issuance. The company completed a 1-for-4 reverse stock split in March 2026 and recently priced a public offering that added to dilution. Trading halts and repeated equity raises have accompanied a decline exceeding 99% over the past 52 weeks, leaving the share price near historic lows. Institutional ownership remains minimal, and the stock shows very large trading-volume swings typical of a speculative, event-driven profile.
Head-to-Head Comparison
The two companies differ markedly in business model and risk profile. FBGL runs a focused, revenue-generating construction business with a clear sector identity and has restored exchange compliance, giving it a more defined operating base. NIVF combines a fertility-services core with newer digital-asset and real-estate ambitions, which widens the opportunity set but also spreads strategic focus thinner.
On momentum, FBGL has seen a sizable yet comparatively contained drawdown, while NIVF has experienced near-total value erosion along with repeated share issuance and multiple reverse splits. Sector exposure varies as well: FBGL is linked to construction and infrastructure demand, whereas NIVF operates in healthcare with an added layer of speculative activity. Both carry liquidity, governance, and execution risks common to micro-cap listings, though the scale and nature of those risks appear materially higher for NIVF.
Tickeron AI Verdict
Based on factors such as trend consistency, capital-structure stability, and catalyst clarity, Tickeron’s AI would likely favor FBGL in the current environment. The company’s restored listing compliance and more contained drawdown point to comparatively stronger positioning, while NIVF’s ongoing dilution and extreme volatility create a less stable risk-reward profile. This view is probabilistic rather than certain, and both stocks merit close monitoring given their speculative micro-cap traits.
Exploring AI Trading Bots for Micro-Cap Monitoring
I’ve found Tickeron’s AI Trading Bots helpful when tracking names like these. The platform offers a range of automated strategies with different timeframes and risk parameters, letting users review performance statistics and see which approaches align with specific objectives. In my experience, reviewing the available metrics can surface ideas worth further research without replacing individual due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
NIVF in -32.25% downward trend, declining for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NIVF declined for three days, in 226 of 230 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for NIVF entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for NIVF just turned positive on October 02, 2026. Looking at past instances where NIVF's MACD turned positive, the stock continued to rise in 8 of 11 cases over the following month. The odds of a continued upward trend are 73%.
Following a +13.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 66 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (208.195). P/E Ratio (0.001) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement